$FCSC News

Last published 5y ago

5y agoMDT SNN XENT IMDC+1Neurent Medical Expands Leadership Team to Support Advancement of In-Office Chronic Rhinitis TreatmentBusiness WireNew Hires Bring Significant ENT and Industry Experience Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced expansions of its leadership team. The hires bring deep medical device i
7y agoXON PTCT FCSC AQBIntrexon Reports Third Quarter 2019 Financial ResultsPR NewswireIntrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the...
7y agoFCSCFibrocell Reports Second Quarter 2019 Financial Results and Recent Operational HighlightsGlobeNewswire- Company to Host Conference Call and Webcast on Thursday, August 15 at 8:30 a.m. EDT - EXTON, Pa., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy...
8y agoFCSCFibrocell Science, Inc. (FCSC) CEO John Maslowski on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
9y agoFCSCFibrocell Science's (FCSC) CEO John Maslowski on Q1 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
9y agoFCSCFibrocell Science's (FCSC) CEO John Maslowski on Full Year 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
9y agoEGRX FCSCEagle Pharmaceuticals Announces David Pernock as President and Chief Commercial OfficerBusiness WireWOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced that David Pernock will join Eagle as President and Chief Commercial Officer, effective January 2017. Mr. Pernock brings vast experience in pharmaceutical and biotechnology leadership to the Company. He will be responsible for all commercial strategy and execution for Eagle’s ...
10y agoFCSCFibrocell Science's (FCSC) CEO David Pernock on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts
12y agoFCSC XONFibrocell Science to Present at 2014 Stem Cell Meeting on the MesaBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that John Maslowski, vice president, scientific affairs of Fibrocell Science will present on Tuesday, October 7 at 2:30 p.m. PDT at the 4th Annu ...
12y agoFCSC XONFibrocell Science to Present at BioCentury NewsMakers of the Biotech Industry ConferenceBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer of Fibrocell Science will present at the BioCentury NewsMakers in the Biotech Industry ...
12y agoFCSC XONFibrocell Science and Intrexon Advance GM-HDF-COL7 toward Clinical Development for the Treatment of Recessive Dystrophic Epidermolysis BullosaBusiness WireEXTON, Pa. & GERMANTOWN, Md.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced plans to file an investigational new drug (IND) application with the U.S. Food ...
12y agoFCSC XONFibrocell Science Hosting R&D Day on September 24, 2014Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will host an R&D Day in New York on September 24, 2014. Presentations by key opinion leaders will include the Company’s lead orphan disea ...
12y agoFCSC XONFibrocell Science, Inc. to Move Stock Listing to NASDAQBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will transfer its U.S. stock exchange listing from the NYSE MKT to The NASDAQ Capital Market. The Company expects its securities to cea ...
12y agoFCSC NBS XONFibrocell Science Reports Second Quarter and First Half 2014 Financial and Operating ResultsBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the second quarter and first half of 2014. The company will host a conference call and webcast today at 8:30 a.m. EDT.
12y agoFCSC XONFibrocell Science to Present at Wedbush 2014 Life Sciences Management Access ConferenceBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer, and Greg Weaver, senior vice president and chief financial officer, of Fibrocell Sci ...
12y agoFCSC XONFibrocell Science to Report Second Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on August 11, 2014Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will report second quarter and first half 2014 financial and operating results on August 11, 2014. David Pernock, chairman and chief ex ...
12y agoFCSC XONFibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy GroupBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that it will present at the 2014 Patient Care Conference of the Dystrophic Epidermolysis Bullosa Research Association of America (De ...
12y agoFCSC XONFIbrocell Science Announces Exclusive Technology License Agreements with UCLA to Advance the Development of Personalized Cell TherapiesBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that it has entered into an exclusive license agreement with The Regents of the University of California. Under the agreement, Fibro ...
12y agoFCSC XONFibrocell Science Receives Orphan Drug Designation for Genetically-Modified Autologous Human Fibroblasts to Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB)Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its genetically-modified autologous human fi ...
12y agoFCSC XONFibrocell Science to Present at Jefferies 2014 Global Healthcare ConferenceBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer, and Greg Weaver, senior vice president and chief financial officer, of Fib ...
12y agoFCSC NBS XONFibrocell Science Announces Plans for Process Development and Manufacturing of Genetically-modified Cell Therapy for Rare Disease, RDEBBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, Inc. (NASDAQ:NBS), has been engaged by Fibrocell’s collaborator, Intrex ...
12y agoFCSC XONFibrocell Science Reports First Quarter 2014 Financial and Operating ResultsBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT: FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the first quarter of 2014. The company will host a conference call and webcast at 5:00 p.m. EDT, today.
12y agoFCSC XONFibrocell Science to Report First Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on May 19, 2014Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will report first quarter 2014 financial and operating results and provide an update on May 19, 2014. The update will include ...
12y agoFCSC XONFibrocell Science Announces Delay in Filing Quarterly Report on Form 10QBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that has filed a Form 12b-25 Notification of Late Filing with the U.S. Securities and Exchange Commission allowing for a five day ext ...
12y agoFCSC XONFibrocell Science to Present at 2nd Annual Regen Med Investor Day and BioCentury Future Leaders in the Biotech Industry ConferenceBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that Gregory Weaver, senior vice president and chief financial officer of Fibrocell Science, will present at the Alliance for Regener ...
12y agoFCSC XONFibrocell Science Reports Fourth Quarter and Full Year 2013 Financial and Operating ResultsBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended Dec. 31, 2013. The company will host a conference call and webcast at 8:3 ...
12y agoFCSC XONFibrocell Science to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on March 17Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that it will report fourth quarter and full-year 2013 financial results and provide an update on the morning of March 17, 2014. The update will include its c ...
12y agoFCSC XONFibrocell Science to Present at Barclays Global Healthcare Conference 2014Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science (NYSEMKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer of Fibrocell Science, will present at the Barclays Global Healthcare Conference 2014 at 2:30 pm EDT on Wedn ...
12y agoFCSC XONFibrocell Science Appoints Robert Sheroff, Vice President of Technical OperationsBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that Robert Sheroff has been appointed vice president of technical operations for the company. In this newly-created position, Mr. Sheroff will be responsibl ...
12y agoFCSC XONFibrocell Science Chairman & CEO David Pernock Joins Board of Alliance for Regenerative MedicineBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced Chairman and CEO David Pernock has joined the board of the Alliance for Regenerative Medicine (ARM), a global advocacy organization whose diverse membership ...
13y agoFCSC XONFibrocell Science Announces Third Quarter 2013 Financial ResultsBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions, particularly those with high unmet medical needs, today announced financial results for the third quarter ended September 30, 2013 and provided an update on recent business developments.
13y agoFCSC XONFibrocell Science Honored with Partner in Progress Award from DEBRA of AmericaBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing innovative products for skin diseases and conditions, today announced the company was honored with a Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA). The award recognizes the company’s recent work devel ...
13y agoFCSCFibrocell Science Announces Exercise of Over-Allotment OptionBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT: FCSC), an autologous cell therapy company primarily focused on developing innovative products for skin diseases and conditions, today announced that the underwriters for its recently announced public offering of common stock partially exercised their over-allotment option to purchase an additional 1,311,698 shares of common stock at a ...
13y agoFCSCFibrocell Science to Present at 2013 Stem Cell Meeting on the MesaBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing innovative products for skin diseases and conditions, announced today that David Pernock, Chairman and Chief Executive Officer, will present at the 3rd Annual Regenerative Medicine Partnering Forum, part of this year’s Stem Cell Meeting on the Mesa held October 1 ...
13y agoFCSCFibrocell Announces Completion of Public Offering of Common StockBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing innovative products for skin diseases and conditions, today announced that it has completed its previously announced underwritten public offering of 11,000,000 shares of common stock at a public offering price of $4.10 per share. The net proceeds to the company, ...
13y agoFCSCFibrocell Science Prices Public Offering of Common StockBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, today announced that it has priced an underwritten public offering of 11,000,000 shares of its common stock at a price of $4.10 per share for aggregate gross proceeds of $45.1 million, prior to ...
13y agoFCSCFibrocell Science Announces Proposed Public Offering of Common StockBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, today announced its intention to offer and sell, shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to ...
13y agoFCSCFibrocell Science, Inc. to Present at Rodman & Renshaw 15th Annual Global Investment ConferenceBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing innovative products for difficult-to-treat skin diseases and conditions where autologous fibroblasts with or without genetic modification can play a key role in addressing unmet medical needs, today announced that David Pernock, Chairman and Chief Executive Offic ...
13y agoFCSCFibrocell Science Appoints Greg Weaver Chief Financial Officer, Senior Vice President, Treasurer and Corporate SecretaryBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today the appointment of Greg Weaver as Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of the Company. Weaver replaces Declan Daly, who will leave t ...
13y agoFCSCFibrocell Science/UCLA Study on the Generation of Clinical Grade iPS Cells Yields Promising ResultsBusiness WireEXTON, Penn.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), announced today positive results from a study demonstrating a potential mechanism for converting research-grade adult skin cells into clinical grade induced pluripotent stem (iPS) cells. The study, entitled “Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinic ...
13y agoFCSCFibrocell Science Extends Patent Protection for LAVIV® (azficel-T) Through 2031Business WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), creator of the first FDA-approved autologous cellular product, LAVIV® (azficel-T) for aesthetics, announced today that the United States Patent and Trademark Office (USPTO) has awarded a patent to the Company which covers azficel-T fibroblast suspension, extending the patent exclusivity in the United States until 2031.
13y agoFCSCFibrocell Science and Intrexon Expand Collaboration for Potential New Class of TherapeuticsBusiness WireEXTON, Pa. & GERMANTOWN, Md.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, and Intrexon Corporation, a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration (ECC) for development of a potentially new class ...
13y agoFCSCFibrocell Science Board of Directors Accepts Resignation of Chief Operating Officer and Chief Financial Officer Declan DalyBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT: FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that Declan Daly, Chief Operating Officer and Chief Financial Officer, will resign to reside in Ireland full time. Fibrocell has initiated an executive search to replace Daly w ...
13y agoFCSCFibrocell Science to Join Russell IndexesBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that it will be included in the Russell Global, the Russell 3000®, and the Russell Microcap Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and glob ...
13y agoFCSCFibrocell Science CEO Rings the New York Stock Exchange Closing BellBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT: FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that Chief Executive Officer and Chairman David Pernock, will preside over the Closing Bell on Tuesday, June 4, 2013 at 4 p.m. Eastern Time at the New York Stock Exchange.